Topic:

M&A

Latest Headlines

Latest Headlines

Endo bets up to $221M on NuPathe and its migraine patch

Endo Health Solutions is extending its makeover with a bolt-on deal, trading $105 million up front for NuPathe to get its hands on the migraine patch Zecuity.

Valeant, Endo chalk up new deals with $220M-plus specialty buys

Valeant Pharmaceuticals has added another $250 million deal to its buyout tally, with a $250 million bid to buy Solta Medical, a maker of dermatological treatment devices. And Endo Health Solutions has  agreed to pay up to $220 million for NuPathe and its brand-new migraine treatment Zecuity.

GlaxoSmithKline bets another $1B on India with a stake-raising buyout offer

GlaxoSmithKline CEO Andrew Witty says he's a "huge bull" on India, despite the ongoing patent-rights tug-of-war between foreign drugmakers and domestic officials. Now, Witty is putting another $1 billion where his mouth is.

Aesthetic device maker Solta Medical sells itself to Valeant Pharmaceuticals for $250M

After layoffs, a sales strategy revamp and spending cuts, Solta Medical has found a buyer to rescue it from its financial and market woes. The Hayward, CA, maker of aesthetic medical devices will sell itself to Valeant Pharmaceuticals for $250 million in cash.

Key Adcock investor rebuffs CFR Pharma's new $1.2B offer

There's nothing like cold, hard cash in your pocket, and that fact may be enough to derail CFR Pharmaceuticals' takeover bid for South Africa's Adcock Ingram. Adcock's top shareholder has rejected a sweetened cash-and-stock offer from CFR, opening a window for rival bidder Bidvest Group to push its counteroffer through.

BGI is building a huge genome database to drive drug discovery

When struggling Complete Genomics went up for sale last year, it sparked a fight between rival sequencing superpowers BGI and Illumina that touched on national security and a host of other big issues. BGI ultimately won and has now begun to outline its plans for its $119 million acquisition.

UPDATED: Accelrys inks $50M Qumas takeover to continue deal-driven expansion

Having acquired Qumas and its electronic regulatory document management capabilities, Accelrys plans to integrate the system with its existing offerings.

Emergent BioSolutions expanding with $222M deal to buy Cangene

Emergent BioSolutions, already the go-to company for anthrax vaccines, will buy Cangene Corp. for about $222 million, adding to its stable of biodefense contracts and picking up a contract manufacturing business that can kick in some additional revenue.

With Given Imaging nearly sold, activist investor Discovery Group has cashed out

Earlier this fall, Given Imaging faced down restive shareholder Discovery Group, which urged the Israeli maker of the PillCam endoscopic camera to explore a sale. Now that Covidien will snatch up the company for $860 million, the activist investor has decided to move on.

Quotient Clinical is the latest CRO snapped up by private equity

U.K. CRO Quotient Clinical is now the property of private equity outfit Bridgepoint Development Capital, joining the crowd of pharma contractors signing up to be acquired in a fast-consolidating industry.